“…Midazolam is commonly used for this purpose, as it does not cause hypotension or hypoxia in regular doses, exhibits a rather short half-life and has a sedative effect that can be reversed by flumazenil [ 6 , 31 , 4 , 73 ]. During the past few years, there has been increasing interest in a new generation benzodiazepine, remimazolam, due to the rapid onset and “deterioration” of its sedative effect along with a more favorable safety profile: remimazolam is not associated with cardiovascular or respiratory suppression, even in older patients or those with ASA >III [ 74 , 30 ].…”